Drug Approvals of 2005
We review new molecular entities approved in 2005, focusing on those in-licensed versus developed internally.
You may also be interested in...
Effectiveness can be evaluated more quickly because researchers won’t have to wait for the second dose, company executive notes during briefing on the launch of the Phase III study.
Confidence in the vaccine has slipped in the US, regardless of political affiliation.
Can "real world evidence" drive consumer health innovation? HBW Insight speaks to Orbital Research’s Chris Bunniss about RWE’s potential for the OTC industry.